Proud to have published our 400th #healthcare & #lifesci report! .Visit @trinity_delta for in-depth coverage on companies including: @parsortix @arecor_plc @avacta #FuturaMedical @hutchmed @redxpharma @scancellpharma #AGL #AREC #AVCT #FUM #HCM #REDX #SCLP

Positive data from @scancellpharma's P2 SCOPE trial in advanced melanoma has led to selection of iSCIB1+ and accelerated plans to move to a P2b/3 registrational study. iSCIB1+ can target more patients, and can improve outcomes vs SoC. For more on #SCLP:.

New IP & Tempus AI collaboration cld support @avacta's product & tech-based business dev. #preCISION pipeline progressing w #AVA6000 Ph I SGC data in H225 & TNBC in H126, & #AVA6103 IND enabling ongoing ahead of 2026 Ph I start. For more on #AVCT:

Data from @scancellpharma cancer vax due 2025: SCOPE Cohort 1&3 (July) & Cohort 4 data (end-25) to inform selection of SCIB1 or iSCIB1+ for Ph 2/3, w/ initial Modi-1 combo data in RCC (Q3). GlyMab Tx subsid provides partnering & funding optionality #SCLP

A healthy @Parsortix Pharma Services pipeline has potential to drive sig mid- & long-term revs; multiple discussions ongoing but deal execution is binary & timing uncertain. A sizeable large pharma or medtech Dx deal cld be financially transformative #AGL

Key 25/26 data from @avacta's lead #preCISION progs: 1) #AVA6000 (FAP-Dox) initial #SGC data late-25 & #TNBC data H126; subject to funding, Phase II in both planned for H126. 2) AVA6103 (FAP-EXd) IND sub late-25, Phase I start Q126 & 1st data Q426 #AVCT

Recent data at #ASCO2025 for @hutchmed's #savolitinib in #NSCLC reassure on the upcoming approval decision in China, and help de-risk the ongoing global Phase III SAFFRON trial with partner @AstraZeneca. For more on #HCM $HCM:.

Large pharma validation of @Parsortix AR, DDR micronuclei, & HER2 CTC assays shld help secure new Pharma Services contracts, providing customers with a broader CTC assay menu across several cancers. For more on #AGL $AGL:

Strategic delivery at @avacta as Dx disposal extends cash into Q126 + pre|CISION assets progress: #AVA6000 (enrolling SGS & TNBC Ph Ib expansion cohorts) & #AVA6103 (candidate selected Ph I start early-26). Multiple '25-26 value inflection points #AVCT

RT @OxBioDynamics: Thanks to former UK Prime Minister Rishi Sunak for visiting Oxford BioDynamics to unveil his role as a Prostate Cancer R….

RT @Parsortix: The recording of the recent @EACRnews - @illumina webinar is now available on the ANGLE website! .C….

H125 results reaffirm that @Scancell has sufficient funds to deliver on key clinical data catalysts during 2025. These include advanced melanoma Phase II #SCIB1 data mid-25, #iSCIB1+ data H225 and Phase I/II #Modi1 data H225. For more on #SCLP $SCLP:.

Large pharma deals key to @Parsortix commercial strategy. 3 deals signed in 2024 progressing well. Pharma Services business has potential to drive significant mid- and longer-term revs via later-stage dev (existing deals, cross-selling, & new deals). #AGL

Home Use study suggests an attractive #WSD4000 profile that cld address the sizeable underserved market for sexual dysfunction in women. Investor focus remains on #Eroxon US traction by @Haleon_health; even modest success wld transform #FuturaMedical #FUM

New funds of £7m, anticipated biz dev income & test revenues from #EpiSwitch PSE and CiRT, shld provide a 12mth cash runway allowing @OxBioDynamics, under new leadership, to seek opportunities to maximise near-term revenues. For more on #OBD

JV divestment sharpens focus onto @hutchmed's core business & proceeds of $608m enable investment into advancing the innovative pipeline, including the next-gen antibody-targeted therapy conjugate (#ATTC) platform. For more on #HCM $HCM

Dec fundraise & @Genmab milestones extends @scancellpharma's cash into H226, beyond key clinical catalysts (Phase II #SCIB1 #iSCIB1+ & Phase I/II #Modi1 data) & gives flexibility to explore BD (for key assets & platforms #GlyMab #AvidiMab). #SCLP $SCLP

✨🎄Merry Christmas from all of us at.@trinity_delta & very best wishes for 2025🎄✨

Upsized £10.3m fundraise extends @scancellpharma's runway to H226, beyond key clinical data for SCIB1/iSCIB1+ and Modi-1 during 2025, and provides time and balance sheet strength to explore potential partnering/out-licencing. For more on $SCLP #SCLP:.

Opt in to #GlyMab deal confirms 2nd @Genmab partnership, providing further validation for @scancellpharma's #antibody platform & immediate non-dilutive funding, with potential for up to $630m in future milestones. For more on $SCLP #SCLP

Our @avacta Outlook reviews the science & opportunity behind pre|CISION & a PDC pipeline designed to target highly potent drugs to the TME expanding their reach & limiting systemic tox. Pipeline progress & Dx divestment are value-inflection points #AVCT